Ranbaxy recalls Lipitor generic batches from US market

Presence of 'foreign substance' feared move may impact consent decree with USFDA

In what could mean a major setback for Ranbaxy Laboratories’ ongoing consent decree with the US regulatory authorities, the company has voluntarily recalled some batches of its generic version of cholesterol-lowering drug from the US market.

“The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles less than 1 mm in size),” Ranbaxy said on the website of its US company (Ranbaxy Pharmaceuticals Inc).

When contacted, the company said it was a temporary disruption in the US and it had already initiated an investigation, which was expected to be over in two weeks, after which it was likely to resume supplies. “The investigation with regard to the issue is expected to be completed within two weeks and thereafter the company expects to resume supplies,” it also said in a statement to the Bombay Stock Exchange (BSE).
 

FACT SHEET
  • Ranbaxy’s 180 days of marketing exclusivity for generic in the US ended on May 29
  • Ranbaxy generated sales of around the $600 million from generic during six-month exclusivity in the US
  • Ranbaxy’s sales from generic came down to $60-65 million in the US after the exclusivity ended
  • Ranbaxy still has 30 per cent share in market in the US
  • generic contributes around 20 per cent to Ranbaxy's total US base business 

Shares of slipped through the day to end at Rs 497.90 on BSE, down 2.89 per cent from yesterday’s close.

Ranbaxy manufactures generic or atorvastatin calcium from two of its facilities — one in the US and another in Mohali. The company refused to disclose the manufacturing location of the recalled batches and did not respond to a detailed questionnaire sent by Business Standard.

According to the company’s US website, Ranbaxy is conducting a voluntary recall for atorvastatin calcium tablets of 10mg, 20mg and 40mg dosage strengths, packaged in 90- and 500-count bottles. The recall does not affect or relate to the 80mg strength, which the company also manufactures.

According to analyst estimates, the three variants of the drug — 10 mg, 20 mg and 40 mg — contribute around 85 per cent of the company’s total revenues from atorvastatin. After its 180-day exclusive marketing period for the generic drug ended in May this year, Ranbaxy’s revenues from atorvastatin were estimated at $60-65 million, analysts said. The drug, which contributed around $600 million during the exclusivity period, is still a major revenue churner for the company.

At present, generic contributes around 20 per cent of the total base revenues of the drug maker from the US, another analyst said.

According to analysts, the latest development is not only significant from the financial point of view, but also because it may have a huge negative impact on the company’s ongoing negotiations with the US Food and Drugs Administration (USFDA) regarding violations found in 2008.

The company, owned by Japan’s Daiichi Sankyo, has had a troubled history in the US. Ranbaxy’s three key Indian facilities — at and (both in Himachal Pradesh) and — have been on the US regulator’s import alert since 2008. FDA had banned 30 generic drugs produced by Ranbaxy at these three units, citing gross violation of approved manufacturing norms. The regulator had also denied marketing approval to new products from these units after it found violations.

However, after negotiating for over two years, Ranbaxy signed a consent decree with the American authorities in December last year, putting an end to the long-running regulatory tussle. Though the settlement allowed the company to resume drug imports from India, it prevented Ranbaxy from manufacturing drugs at the Paonta Sahib, Batamandi, and Gloversville facilities for introduction to the and for the President’s Emergency Plan for AIDS Relief programme until drugs could be produced at such facilities in compliance with the US manufacturing quality standards.

“The category or class of recall is not known yet. If it is a case of contamination, it could be serious, mainly in the context of the ongoing settlement with USFDA,” one of the analysts said.

The development may also impact the pending approval of Ranbaxy’s generic version of hypertension drug Diovan, for which Ranbaxy is expected to have a 180-day exclusive marketing period. Approval for the drug is already facing delay and the latest development may increase troubles for the company.

“This recall (of atorvastatin) is being conducted with the full knowledge of USFDA,” the company said on its US website.

image
Business Standard
177 22
Business Standard

Ranbaxy recalls Lipitor generic batches from US market

Presence of 'foreign substance' feared move may impact consent decree with USFDA

BS Reporter  |  New Delhi 



In what could mean a major setback for Ranbaxy Laboratories’ ongoing consent decree with the US regulatory authorities, the company has voluntarily recalled some batches of its generic version of cholesterol-lowering drug from the US market.

“The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles less than 1 mm in size),” Ranbaxy said on the website of its US company (Ranbaxy Pharmaceuticals Inc).

When contacted, the company said it was a temporary disruption in the US and it had already initiated an investigation, which was expected to be over in two weeks, after which it was likely to resume supplies. “The investigation with regard to the issue is expected to be completed within two weeks and thereafter the company expects to resume supplies,” it also said in a statement to the Bombay Stock Exchange (BSE).
 

FACT SHEET
  • Ranbaxy’s 180 days of marketing exclusivity for generic in the US ended on May 29
  • Ranbaxy generated sales of around the $600 million from generic during six-month exclusivity in the US
  • Ranbaxy’s sales from generic came down to $60-65 million in the US after the exclusivity ended
  • Ranbaxy still has 30 per cent share in market in the US
  • generic contributes around 20 per cent to Ranbaxy's total US base business 

Shares of slipped through the day to end at Rs 497.90 on BSE, down 2.89 per cent from yesterday’s close.

Ranbaxy manufactures generic or atorvastatin calcium from two of its facilities — one in the US and another in Mohali. The company refused to disclose the manufacturing location of the recalled batches and did not respond to a detailed questionnaire sent by Business Standard.

According to the company’s US website, Ranbaxy is conducting a voluntary recall for atorvastatin calcium tablets of 10mg, 20mg and 40mg dosage strengths, packaged in 90- and 500-count bottles. The recall does not affect or relate to the 80mg strength, which the company also manufactures.

According to analyst estimates, the three variants of the drug — 10 mg, 20 mg and 40 mg — contribute around 85 per cent of the company’s total revenues from atorvastatin. After its 180-day exclusive marketing period for the generic drug ended in May this year, Ranbaxy’s revenues from atorvastatin were estimated at $60-65 million, analysts said. The drug, which contributed around $600 million during the exclusivity period, is still a major revenue churner for the company.

At present, generic contributes around 20 per cent of the total base revenues of the drug maker from the US, another analyst said.

According to analysts, the latest development is not only significant from the financial point of view, but also because it may have a huge negative impact on the company’s ongoing negotiations with the US Food and Drugs Administration (USFDA) regarding violations found in 2008.

The company, owned by Japan’s Daiichi Sankyo, has had a troubled history in the US. Ranbaxy’s three key Indian facilities — at and (both in Himachal Pradesh) and — have been on the US regulator’s import alert since 2008. FDA had banned 30 generic drugs produced by Ranbaxy at these three units, citing gross violation of approved manufacturing norms. The regulator had also denied marketing approval to new products from these units after it found violations.

However, after negotiating for over two years, Ranbaxy signed a consent decree with the American authorities in December last year, putting an end to the long-running regulatory tussle. Though the settlement allowed the company to resume drug imports from India, it prevented Ranbaxy from manufacturing drugs at the Paonta Sahib, Batamandi, and Gloversville facilities for introduction to the and for the President’s Emergency Plan for AIDS Relief programme until drugs could be produced at such facilities in compliance with the US manufacturing quality standards.

“The category or class of recall is not known yet. If it is a case of contamination, it could be serious, mainly in the context of the ongoing settlement with USFDA,” one of the analysts said.

The development may also impact the pending approval of Ranbaxy’s generic version of hypertension drug Diovan, for which Ranbaxy is expected to have a 180-day exclusive marketing period. Approval for the drug is already facing delay and the latest development may increase troubles for the company.

“This recall (of atorvastatin) is being conducted with the full knowledge of USFDA,” the company said on its US website.

RECOMMENDED FOR YOU

Ranbaxy recalls Lipitor generic batches from US market

Presence of 'foreign substance' feared move may impact consent decree with USFDA

In what could mean a major setback for Ranbaxy Laboratories’ ongoing consent decree with the US regulatory authorities, the company has voluntarily recalled some batches of its generic version of cholesterol-lowering drug Lipitor from the US market.

In what could mean a major setback for Ranbaxy Laboratories’ ongoing consent decree with the US regulatory authorities, the company has voluntarily recalled some batches of its generic version of cholesterol-lowering drug from the US market.

“The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles less than 1 mm in size),” Ranbaxy said on the website of its US company (Ranbaxy Pharmaceuticals Inc).

When contacted, the company said it was a temporary disruption in the US and it had already initiated an investigation, which was expected to be over in two weeks, after which it was likely to resume supplies. “The investigation with regard to the issue is expected to be completed within two weeks and thereafter the company expects to resume supplies,” it also said in a statement to the Bombay Stock Exchange (BSE).
 

FACT SHEET
  • Ranbaxy’s 180 days of marketing exclusivity for generic in the US ended on May 29
  • Ranbaxy generated sales of around the $600 million from generic during six-month exclusivity in the US
  • Ranbaxy’s sales from generic came down to $60-65 million in the US after the exclusivity ended
  • Ranbaxy still has 30 per cent share in market in the US
  • generic contributes around 20 per cent to Ranbaxy's total US base business 

Shares of slipped through the day to end at Rs 497.90 on BSE, down 2.89 per cent from yesterday’s close.

Ranbaxy manufactures generic or atorvastatin calcium from two of its facilities — one in the US and another in Mohali. The company refused to disclose the manufacturing location of the recalled batches and did not respond to a detailed questionnaire sent by Business Standard.

According to the company’s US website, Ranbaxy is conducting a voluntary recall for atorvastatin calcium tablets of 10mg, 20mg and 40mg dosage strengths, packaged in 90- and 500-count bottles. The recall does not affect or relate to the 80mg strength, which the company also manufactures.

According to analyst estimates, the three variants of the drug — 10 mg, 20 mg and 40 mg — contribute around 85 per cent of the company’s total revenues from atorvastatin. After its 180-day exclusive marketing period for the generic drug ended in May this year, Ranbaxy’s revenues from atorvastatin were estimated at $60-65 million, analysts said. The drug, which contributed around $600 million during the exclusivity period, is still a major revenue churner for the company.

At present, generic contributes around 20 per cent of the total base revenues of the drug maker from the US, another analyst said.

According to analysts, the latest development is not only significant from the financial point of view, but also because it may have a huge negative impact on the company’s ongoing negotiations with the US Food and Drugs Administration (USFDA) regarding violations found in 2008.

The company, owned by Japan’s Daiichi Sankyo, has had a troubled history in the US. Ranbaxy’s three key Indian facilities — at and (both in Himachal Pradesh) and — have been on the US regulator’s import alert since 2008. FDA had banned 30 generic drugs produced by Ranbaxy at these three units, citing gross violation of approved manufacturing norms. The regulator had also denied marketing approval to new products from these units after it found violations.

However, after negotiating for over two years, Ranbaxy signed a consent decree with the American authorities in December last year, putting an end to the long-running regulatory tussle. Though the settlement allowed the company to resume drug imports from India, it prevented Ranbaxy from manufacturing drugs at the Paonta Sahib, Batamandi, and Gloversville facilities for introduction to the and for the President’s Emergency Plan for AIDS Relief programme until drugs could be produced at such facilities in compliance with the US manufacturing quality standards.

“The category or class of recall is not known yet. If it is a case of contamination, it could be serious, mainly in the context of the ongoing settlement with USFDA,” one of the analysts said.

The development may also impact the pending approval of Ranbaxy’s generic version of hypertension drug Diovan, for which Ranbaxy is expected to have a 180-day exclusive marketing period. Approval for the drug is already facing delay and the latest development may increase troubles for the company.

“This recall (of atorvastatin) is being conducted with the full knowledge of USFDA,” the company said on its US website.

image
Business Standard
177 22
Widgets Magazine

More News

  • Airtel deploys carrier aggregation technology to offer better data speed in  Mumbai Airtel to offer 100 mbps data speed in Mumbai via advanced tech
  • CCI slaps over Rs 6,700 crore fine on 11 cement companies CCI slaps Rs 6,700-crore fine on 11 cement firms
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard